Search results
Results from the WOW.Com Content Network
The causes of persisting symptoms are a combination of pharmacological factors such as persisting drug induced receptor changes, psychological factors both caused by the drug and separate from the drug and possibly in some cases, particularly high dose users, structural brain damage or structural neuronal damage.
A study found that of 42 patients treated with alprazolam, up to a third of long-term users of the benzodiazepine drug alprazolam develop depression. [40] Studies have shown that long-term use of benzodiazepines and the benzodiazepine receptor agonist nonbenzodiazepine Z drugs are associated with causing depression as well as a markedly raised ...
Alprazolam, sold under the brand name Xanax among others, is a fast-acting, potent tranquilizer of moderate duration within the triazolobenzodiazepine group of chemicals called benzodiazepines. [15] Alprazolam is most commonly prescribed in the management of anxiety disorders , especially panic disorder and generalized anxiety disorder (GAD). [ 9 ]
Joint pain is a common symptom we all experience at some point or another. Painful joints can have a significant impact on quality of life and the ability to do daily activities.
"Joint pain, like any other pain in the body, is a signal that something may not be working properly in our musculoskeletal system," says Dr. Jeffrey Zarin, MD, an orthopedic surgeon specializing ...
The tables below contain a sample list of benzodiazepines and benzodiazepine analogs that are commonly prescribed, with their basic pharmacological characteristics, such as half-life and equivalent doses to other benzodiazepines, also listed, along with their trade names and primary uses.
Osteoarthritis is a condition that can affect joint mobility and cause joint pain. Experts are interested in understanding the relationship between experiencing menopause and the risk for ...
APA does not recommend benzodiazepines for persons with depressive symptoms or a recent history of substance use disorder. APA guidelines state that, in general, pharmacotherapy of panic disorder should be continued for at least a year, and that clinical experience supports continuing benzodiazepine treatment to prevent recurrence.